Chronic Lymphocytic Leukemia

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL.

NCT05254743

Sponsor: Eli Lilly and Company (Loxo Oncology, Inc)

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:

Participants will receive either pirtobruitinib (investigational drug) or ibrutinib.